Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.23 -4.7%	$1.33	$0.86 ▼ $3.78	$269.04M	0.31	3.27 million shs	3.63 million shs
CLLS Cellectis	$1.47 +5.0%	$1.48	$1.10 ▼ $2.43	$81.71M	2.92	143,257 shs	77,868 shs
PRTA Prothena	$5.72 -0.5%	$7.06	$4.32 ▼ $25.42	$307.89M	-0.08	755,521 shs	3.57 million shs
RCKT Rocket Pharmaceuticals	$2.70 -4.6%	$5.31	$2.19 ▼ $26.98	$288.32M	0.68	2.12 million shs	7.23 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-4.65%	-8.21%	+10.81%	-24.07%	-44.84%
CLLS Cellectis	+6.52%	+10.53%	-3.29%	+13.08%	-27.05%
PRTA Prothena	-0.52%	+12.60%	-16.13%	-55.90%	-70.73%
RCKT Rocket Pharmaceuticals	-4.59%	-7.85%	-59.03%	-67.97%	-86.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.2341 of 5 stars	4.5	3.0	0.0	0.0	3.3	0.6
CLLS Cellectis	3.3787 of 5 stars	3.5	5.0	0.0	2.3	2.5	0.6
PRTA Prothena	3.5885 of 5 stars	4.2	4.0	0.0	1.9	1.7	1.3
RCKT Rocket Pharmaceuticals	4.9192 of 5 stars	4.2	4.0	4.7	2.2	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	586.54% Upside
CLLS Cellectis	3.00	Buy	$4.00	172.11% Upside
PRTA Prothena	2.33	Hold	$31.50	450.70% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	588.89% Upside

Current Analyst Ratings Breakdown

Latest CLLS, RCKT, PRTA, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,451.90	N/A	N/A	$2.01 per share	0.61
CLLS Cellectis	$49.22M	1.66	N/A	N/A	$2.36 per share	0.62
PRTA Prothena	$135.16M	2.28	N/A	N/A	$9.05 per share	0.63
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	N/A	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest CLLS, RCKT, PRTA, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
CLLS Cellectis	0.44	1.67	1.67
PRTA Prothena	N/A	9.00	9.00
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CLLS Cellectis	63.90%
PRTA Prothena	97.08%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CLLS Cellectis	16.41%
PRTA Prothena	9.20%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

CLLS, RCKT, PRTA, and ALLO Headlines

Recent News About These Companies

Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

June 20 at 3:00 PM | businesswire.com

INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Robbins Geller

June 20 at 2:30 PM | globenewswire.com

Faruqi & Faruqi Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

June 20 at 11:41 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against RCKT

June 20 at 9:31 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT

June 20 at 9:00 AM | prnewswire.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

June 19 at 5:59 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 19 at 4:00 PM | globenewswire.com

Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

June 19 at 9:00 AM | prnewswire.com

ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) INVESTOR ALERT: Investors With Large Losses in Rocket Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

June 19 at 8:15 AM | globenewswire.com

RCKT INVESTOR NOTICE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 19 at 4:30 AM | businesswire.com

UBS Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

June 19 at 1:43 AM | americanbankingnews.com

Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

June 18 at 7:30 PM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

June 18 at 12:42 PM | globenewswire.com

RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 18 at 11:30 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

June 18 at 11:18 AM | globenewswire.com

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders

June 18 at 9:29 AM | globenewswire.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

June 17, 2025 | prnewswire.com

Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025

June 17, 2025 | accessnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $5.00 by Analysts at UBS Group

June 17, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

June 17, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

June 17, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, RCKT, PRTA, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.23 -0.06 (-4.65%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.03 (+2.11%)

As of 06/20/2025 07:57 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Cellectis NASDAQ:CLLS

$1.47 +0.07 (+5.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.44 -0.02 (-1.70%)

As of 06/20/2025 05:57 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Prothena NASDAQ:PRTA

$5.72 -0.03 (-0.52%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$5.83 +0.11 (+1.91%)

As of 06/20/2025 07:46 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.70 -0.13 (-4.59%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.72 +0.02 (+0.74%)

As of 06/20/2025 07:59 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time